Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-07-17FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for venlafaxine hydrochloride from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2014-07-17FDA Approved: DOXEPIN HYDROCHLORIDE — Supplemental Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s supplemental application for doxepin hydrochloride, updating the previously approved abbreviated new drug appl…
-
FDA approval · 2014-07-17FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for venlafaxine hydrochloride (generic) from Dr. Reddy's Laboratories Limited. This action approves …
-
FDA approval · 2014-07-17FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved Alembic Pharmaceuticals' supplemental application for a generic venlafaxine product (ANDA 078932). Venlafaxine is indicated…
-
FDA approval · 2014-07-17FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Venlafaxine hydrochloride, a generic venlafaxine product from Aurobindo Pharma Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-07-09Clinical Trial Update: An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder [Phase 4]
This is an open-label Phase 4 trial evaluating duloxetine for irritable bowel syndrome with comorbid generalized anxiety disorder. The study…
-
FDA approval · 2014-07-08FDA Approved: LEXAPRO — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Lexapro (escitalopram) submitted by Allergan, Inc.
-
FDA approval · 2014-06-30FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for venlafaxine hydrochloride from Teva Pharmaceuticals USA, Inc., marking an approval action un…
-
FDA approval · 2014-06-26FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for venlafaxine hydrochloride from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2014-06-26FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for venlafaxine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
-
FDA approval · 2014-06-18FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Venlafaxine hydrochloride from Aurobindo Pharma Limited.
-
FDA approval · 2014-06-17FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for venlafaxine from BluePoint Laboratories under ANDA077653. This action authorizes a generic versi…
-
FDA approval · 2014-06-11FDA Approved: DULOXETINE DELAYED-RELEASE — Original Application (Breckenridge Pharmaceutical, Inc.)
FDA approved Breckenridge Pharmaceutical's original generic duloxetine hydrochloride delayed-release capsules, a generic version of the anti…
-
FDA approval · 2014-06-09FDA Approved: DULOXETINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original ANDA for duloxetine hydrochloride, establishing a generic version of duloxetine.
-
CLINICAL_TRIALS trial_result · 2014-05-23Clinical Trial Update: SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) [Phase 2]
Phase 2 clinical trial update for SPD503 in children and adolescents with generalized anxiety disorder, separation anxiety disorder, or soci…
-
FDA approval · 2014-05-20FDA Approved: ESCITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for escitalopram oxalate by Aurobindo Pharma Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder [Phase 3]
This document reports a Phase 3 trial evaluating the efficacy and safety of Gabitril (tiagabine) in adults with generalized anxiety disorder…
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder. [Phase 3]
A Phase 3 study evaluating the safety and efficacy of GABITRIL for adults with Generalized Anxiety Disorder has completed.
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of Gabitril (tiagabine) in adults with generalized anxiety disorder has complete…
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder [Phase 3]
This clinical trial update reports the completion of a Phase 3 10-week efficacy and safety study of Gabitril (tiagabine) in adults with Gene…
-
CLINICAL_TRIALS trial_result · 2014-04-23Clinical Trial Update: Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder [Phase 4]
Phase 4 trial evaluating the combination of Paroxetine CR and Quetiapine for refractory generalized anxiety disorder; results were posted af…
-
CLINICAL_TRIALS trial_result · 2014-04-16Clinical Trial Update: Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder [Phase 4]
A Phase 4 trial of ziprasidone for generalized anxiety disorder in patients with bipolar disorder was terminated, with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2014-03-10Clinical Trial Update: Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS [Phase 3]
Phase 3 study evaluating escitalopram (Lexapro) for generalized anxiety disorder in patients with HIV infection has completed, with results …
-
CLINICAL_TRIALS trial_result · 2014-03-10Clinical Trial Update: False Safety Behavior Elimination Therapy: A Randomized Study of a Brief Individual Transdiagnostic Treatment for Anxiety Disorders [NA]
This clinical trial update reports the completion of a randomized study evaluating a brief, transdiagnostic therapy called False Safety Beha…
-
CLINICAL_TRIALS trial_result · 2014-03-05Clinical Trial Update: A Study in Pediatric Participants With Generalized Anxiety Disorder [Phase 3]
A Phase 3 pediatric study for generalized anxiety disorder has completed, with results posted in March 2014.